bb-1701
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 29, 2020 (NCT04257110)
Timeline
Indications
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Payload
- eribulin
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314978 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06188559 | Phase 2 | Apr 10, 2024 | Bliss Biopharmaceutical Co., Ltd, Eisai |
| NCT04257110 | Phase 1 | Feb 29, 2020 | Bliss Biopharmaceutical Co., Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bliss Biopharmaceutical Co., Ltd | For profit | 2 | 1 | 2 | 2020 |
| Eisai | For profit | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1